Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction - PubMed
3 hours ago
- #Cardiometabolic HFpEF
- #ARNi
- #Female sex
- Study explores benefits of sacubitril/valsartan alone and combined with dapagliflozin in a female preclinical model of cardiometabolic and age-related cardiac dysfunction.
- Research conducted under ethical approval from the Local Ethical Committee and Ministry of Health, following ARRIVE guidelines.
- No competing interests declared by the authors.
- References highlight sex differences in heart failure with preserved ejection fraction (HFpEF), including pathophysiology, diagnosis, and therapeutic strategies.
- Funding sources include MNESYS/NEXTGENERATIONEU and PRIN 2022 from the Italian Ministry of University and Research.